API SUPPLIERS

API Suppliers

35

US DMFs Filed

14

CEP/COS Certifications

JDMFs Filed

Other Certificates

Other Suppliers

API REF. PRICE (USD / KG)

914

API Market Place

5

INTERMEDIATES

2

DOSSIERS // FDF

USA (Orange Book)

21

Europe

126

Canada

0

Australia

1

South Africa

10

Uploaded Dossiers

33

GLOBAL SALES (USD Million)

U.S. Medicaid

388.00

Annual Reports

0

FDF Market Place

3

EXCIPIENTS

215

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

0

USFDA Exclusivities

0

DIGITAL CONTENT

Blog #PharmaFlow

0

News

6

REF STANDARD

EDQM

0

USP

2

JP

0

Other Listed Suppliers

2

SERVICES

0

Full Screen View

Chugai Pharmaceutical

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Transfer and Future Marketing of Osteoporosis Agent Bonviva in Japan

Details:

Bonviva is a medicine that contains the active substance ibandronic acid. It is available as tablets (150 mg) and as a solution for injection in a prefilled syringe (3 mg).

Lead Product(s): Ibandronate Sodium

Therapeutic Area: Musculoskeletal Product Name: Bonviva

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Taisho Pharmaceutical

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 24, 2022

ASK
US

Upload
your Marketing & Sales content

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Find Drugs in Development News & Deals for Ibandronate Sodium

Ibandronate Sodium

Ibandronate Sodium

Synopsis

Chemistry

APIs // Active Pharmaceutical Ingredients

35 API Suppliers

14 USDMF

2 CEP/COS

1 JDMF

7 EU WC

25 KDMF

5 NDC API

19 Listed Suppliers

DEVELOPMENTS

1 Drug(s) in Development

PRICE INFORMATION

API Reference Price

API Exports

API Imports

FDF Imports

INTERMEDIATES

2 Suppliers

DOSSIERs // Finished Dosage Formulations

191 Dossiers

21 FDA Orange Book

126 Europe

1 Australia

10 South Africa

33 Listed Dossiers

DRUG PRODUCT COMPOSITION

TABLET;ORAL - EQ 150MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL - EQ 2.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

INJECTABLE;INTRAVENOUS - EQ 3MG BASE/3ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

Suppliers

31 Kerry

22 BASF

19 Roquette

13 Microlex e.U

11 Sigachi Industries

10 Corel Pharma Chem

10 Gangwal Healthcare

8 Gangwal Chemicals

8 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd

7 Seppic

7 Ideal Cures Pvt Ltd

6 Lonza Capsugel

5 DFE Pharma

5 Nanjing Well Pharmaceutical

5 Actylis

4 Shanghai Shenmei Pharmaceutical Technology Co., Ltd

4 SPI Pharma

4 Prachin Chemical

3 Kima Chemical

3 Vasa Pharmachem

3 Pharmatrans-Sanaq

2 DKSH

2 Nomisma Healthcare

2 Seqens

2 Finar

2 Jai Radhe Sales

2 The Dow Chemical Company

1 Shijiazhuang Huaxu Pharmaceutical

1 NEWEDGE Overseas

1 Rochem International Inc

1 Chynops Pharma

1 Boai NKY Pharmaceuticals Ltd

1 Clariant

1 Alcedo Pharmachem

1 Minakem

1 Ingredion Pharma Solutions

1 Zhejiang Huakang Pharmaceutical

1 Ulanqab Kema New Material

1 Aeon Procare

1 ACG Worldwide

1 Qianhao Chemical (Hebei) Co., Ltd

1 Qualicaps

EXCIPIENTS BY APPLICATIONS

58 Fillers, Diluents & Binders

TABLET;ORAL - EQ 150MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET;ORAL - EQ 2.5MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

INJECTABLE;INTRAVENOUS - EQ 3MG BASE/3ML Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons